NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study

Sarcopenia is associated with NAFLD. It is unknown if the association is explained by shared risk factors. Our study sought to investigate the association between liver fat and sarcopenia in our cohort. Liver fat was measured on CT between 2008 and 2011. We excluded heavy alcohol use and missing covariates. Muscle mass in a subset (n = 485) was measured by 24 h urinary creatinine. Physical function was defined by h strength and walking speed. Sarcopenia was defined as low muscle mass and/or low physical function. We created multivariable-adjusted regression models to evaluate cross-sectional associations between liver fat and low muscle mass, grip strength, and walking speed. The prevalence of hepatic steatosis was 30% (n = 1073; 58.1% women; mean age 65.8 ± 8.6 years). There was a significant positive association between liver fat and muscle mass in linear regression models. The association was not significant after adjusting for BMI. The odds of sarcopenia increased by 28% for each SD in liver fat (OR 1.28; 95% CI 1.02, 1.60) and persisted after accounting for confounders in multivariable-adjusted models (OR 1.30, 95% CI 1.02, 1.67). Further studies are needed to determine if there is a causal relationship between liver fat and sarcopenia and whether treatment of sarcopenia improves liver fat.

Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease

The association between the pathogenesis and natural course of nonalcoholic fatty liver disease (NAFLD) and skeletal muscle dysfunction is increasingly recognized. These obesity-associated disorders originate primarily from sustained caloric excess, gradually disrupting cellular and molecular mechanisms of the adipose-muscle-liver axis resulting in end-stage tissue injury exemplified by cirrhosis and sarcopenia. These major clinical phenotypes develop through complex organ-tissue interactions from the earliest stages of NAFLD. While the role of adipose tissue expansion and remodeling is well established in the development of NAFLD, less is known about the specific interplay between skeletal muscle and the liver in this process. Here, the relationship between skeletal muscle and liver in various stages of NAFLD progression is reviewed. Current knowledge of the pathophysiology is summarized with the goal of better understanding the natural history, risk stratification, and management of NAFLD.

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb

BACKGROUND

In 2016, the FDA approved infliximab-dyyb (IFX-dyyb) as a biosimilar to infliximab (IFX). Deemed to have comparable efficacy and safety to IFX, IFX-dyyb is 20%-30% less expensive, allowing significant cost savings for institutions and some payers. In 2018, IFX was reported to be the drug with the highest spend since 2013, costing $3.8 billion; however, transition to IFX-dyyb would save $1.1 billion. Regardless, many institutions have not transitioned to IFX-dyyb or other IFX biosimilars (e.g., IFX-abda) because of concerns about clinical outcomes, uncertainty regarding financial impact, and barriers to operationalizing biosimilar adoption. At Boston Medical Center, a decision was made in March 2018 to adopt IFX-dyyb and transition patients who have been on IFX for ≥ 6 months for all indications to IFX-dyyb.

OBJECTIVES

To (a) describe a biosimilar adoption process of IFX-dyyb in patients on IFX for ≥ 6 months; (b) characterize cost savings of transitioning patients to IFX-dyyb; and (c) evaluate real-world clinical outcomes of adult patients with inflammatory bowel disease (IBD) who transitioned to IFX-dyyb.

METHODS

This is a retrospective cohort study of patients eligible for the IFX-dyyb switch from March 2018 to June 2019 at a large academic medical center. For process outcomes, we collected the proportion of patients who transitioned to IFX-dyyb and calculated the cost savings generated. To assess clinical outcomes of adult IBD patients who transitioned, we collected IFX and IFX-dyyb dosage, Harvey Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) scores, c-reactive protein (CRP) levels, and colonoscopy results. Descriptive statistics, Wilcoxon signed-rank test, and McNemar's test were used for statistical analyses.

RESULTS

Of 151 eligible patients, 146 (97%) successfully transitioned to IFX-dyyb. Based on our conversion rate to IFX-dyyb, our health system is forecasted to save approximately $500,000 annually. From March to June 2018, 63 of 75 (84%) eligible IBD patients transitioned from IFX to IFX-dyyb. In this cohort, of the 40 patients with HBI or SCCAI scores before and after transition, 36 (90%) maintained remission. For 32 patients, the mean CRP (SD) before transition was 11.2 (22) and 4.1 (4.8) after transition (P = 0.09). Since the IFX-dyyb transition, 9 patients had a colonoscopy, of which 5 (56%) were in endoscopic remission. As of October 2018, 56 (89%) patients continued with IFX-dyyb after transition. Of the 46 patients who had 12-15 months posttransition data, 38 (83%) remained on IFX-dyyb.

CONCLUSIONS

Implementation of a biosimilar adoption program can be successful and result in significant cost savings without compromising clinical outcomes. A model that uses actionable strategies and embraces collaboration among stakeholders is described here, with outcomes demonstrating successful IFX-dyyb uptake and no changes in clinical outcomes of transitioned adult patients with IBD.

DISCLOSURES

No outside funding supported this study. Farraye reports advisory board fees from Janssen, Merck, and Pfizer. Shah reports speaker fees from Pfizer. The other authors have nothing to disclose.

Trends in total ankle arthroplasty and revisions in the Medicare database

Background

High failure rates and unacceptable patient outcomes have kept total ankle arthroplasty (TAA) from becoming a favorable treatment option. Modern prosthetic designs and techniques have improved outcomes and decreased revision rates. Current literature has not adequately investigated the recent trends in TAA utilization and revision rate. The purpose of this study was to determine the trends in TAA utilization and the rate of revision TAA by analyzing a comprehensive Medicare database for procedures performed between 2005 and 2012.

Methods

A retrospective review of a comprehensive Medicare database within the PearlDiver Supercomputer application (Warsaw, IN) of the index procedures TAA and revision TAA was conducted. Patients who underwent TAA and revision TAA were identified by Current Procedural Terminology (CPT)-27702, 27703, and International Classification of Disease ninth revision (ICD) codes 81.56, 81.59 respectively. The primary outcomes of this study were annual revision incidence and TAA annual utilization. Demographic data such as age, gender, and geographical location of patients were also examined.

Results

Within our study period of 2005-2012 there was a reported total of 7,181 TAAs and 1,431 revision TAAs which is a revision incidence of 19.928% amongst the Medicare population. The compound annual growth rate (CAGR) was 16.37% for TAA, 7.74% for revision TAA, and a mean 7.41% annual revision incidence. Amongst females there were 3,568 TAA and 731 revision TAA compared with 3,336 TAA and 613 revision TAA amongst males. The greatest amount of TAA and revision TAA were found in the 65-69 age group followed by the 70-74 age group. Regionally, the highest number of TAA and revision TAA were found in the South and the lowest in the Northeast.

Conclusions

Our analysis of the Medicare database shows that there is a high rate of annual growth in TAA utilization (16.37%) and revision TAA (7.74%) indicating that there is an increased demand for TAA in the Unites States. However, failed TAA can have serious consequence and revision TAA remains to have suboptimal results. This study highlights the recent trends in ankle arthroplasty and serves to increase awareness of this increasingly popular procedure.